FOLLOWUS
Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula
- Chinese Journal of Integrative Medicine Vol. 23, Issue 1, Pages: 25-32(2017)
- Affiliations：
1. Institute of Chinese Medicine, Chinese University of Hong Kong,Hong Kong,China
2. State Key Laboratory of Phytochemistry and Plant Resources in West China, Chinese University of Hong Kong,Hong Kong,China
3. Department of Orthopaedics and Traumatology, Chinese University of Hong Kong,Hong Kong,China
- Author bio：
- Funds：
DOI：10.1007/s11655-016-2474-5
CLC：Published：2017，
Published Online：14 June 2016，
Scan for full text
Siu, Ws., Ko, Ch., Wong, Hl. et al. Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula., Chin. J. Integr. Med. 23, 25–32 (2017). https://doi.org/10.1007/s11655-016-2474-5
Wing-sum Siu, Chun-hay Ko, Hing-lok Wong, et al. Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula. [J]. Chinese Journal of Integrative Medicine 23(1):25-32(2017)
Siu, Ws., Ko, Ch., Wong, Hl. et al. Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula., Chin. J. Integr. Med. 23, 25–32 (2017). https://doi.org/10.1007/s11655-016-2474-5 DOI：
Wing-sum Siu, Chun-hay Ko, Hing-lok Wong, et al. Seropharmacological study on osteogenic effects of post-absorption ingredients of an osteoprotective herbal formula. [J]. Chinese Journal of Integrative Medicine 23(1):25-32(2017) DOI： 10.1007/s11655-016-2474-5.
摘要
To further investigate the {ptin vitro} effects of an osteoprotective herbal formula "ELP" (Herba Epimedii
Fructus Ligustri Lucidi and Fructus Psoraleae) using seropharmacological approach. Rats were fed with ELP or its individual component herbs for 2 days. The serum containing the postabsorbed ingredients of the herbal items were collected for cell culture using UMR106 cell
RAW264.7 cell and mesenchymal stem cell (MSC) isolated from the bone marrow of the rats. The effects of the herbal-containing serum on cell toxicity were detected by 3-[4
5-dimethylthiazol-2-yl]-2
5-diphenyltetrazolium bromide assay; bromodeoxyuridine assay was conducted to measure the cell proliferation of UMR106 cell and MSC; cell activity was measured using colorimetric method
and mRNA expression of runt-related transcription factor 2 (Runx2)
alkaline phosphatase (ALP) and osteopontin (OPN) of UMR106 and MSC as well as matrix metalloproteinase 9 (MMP-9)
tartrate-resistant acid phosphatase (TRAP) and cathepsin K of RAW264.7 were analyzed using real-time reverse-transcription polymerase chain reaction. ELP and its component serum exhibited no cytotoxic effects on the cells. The ELP-containing serum increased the proliferation of UMR106 cell and MSC by 25.7% and 14.4 %
respectively and the alkaline phosphatase activity of MSC was increased by 42.6%. On the contrary
it inhibited the RAW264.7 cell differentiation by 29.2 %. ELP serum upregulated the Runx2 expression of UMR and MSC by 1.18 fold and 1.27 fold
respectively. It also upregulated ALP and OPN expression in MSC by 1.69- and 2.12-fold
respectively. On the other hand
ELP serum down-regulated MMP-9 and cathepsin K expression of RAW264.7 cell by 0.46- and 0.36-fold
respectively. The serum of the animals fed with ELP contains active ingredients which are effective in promoting osteogenesis and inhibiting osteoclastogenesis.
Abstract
To further investigate the {ptin vitro} effects of an osteoprotective herbal formula "ELP" (Herba Epimedii
Fructus Ligustri Lucidi and Fructus Psoraleae) using seropharmacological approach. Rats were fed with ELP or its individual component herbs for 2 days. The serum containing the postabsorbed ingredients of the herbal items were collected for cell culture using UMR106 cell
RAW264.7 cell and mesenchymal stem cell (MSC) isolated from the bone marrow of the rats. The effects of the herbal-containing serum on cell toxicity were detected by 3-[4
5-dimethylthiazol-2-yl]-2
5-diphenyltetrazolium bromide assay; bromodeoxyuridine assay was conducted to measure the cell proliferation of UMR106 cell and MSC; cell activity was measured using colorimetric method
and mRNA expression of runt-related transcription factor 2 (Runx2)
alkaline phosphatase (ALP) and osteopontin (OPN) of UMR106 and MSC as well as matrix metalloproteinase 9 (MMP-9)
tartrate-resistant acid phosphatase (TRAP) and cathepsin K of RAW264.7 were analyzed using real-time reverse-transcription polymerase chain reaction. ELP and its component serum exhibited no cytotoxic effects on the cells. The ELP-containing serum increased the proliferation of UMR106 cell and MSC by 25.7% and 14.4 %
respectively and the alkaline phosphatase activity of MSC was increased by 42.6%. On the contrary
it inhibited the RAW264.7 cell differentiation by 29.2 %. ELP serum upregulated the Runx2 expression of UMR and MSC by 1.18 fold and 1.27 fold
respectively. It also upregulated ALP and OPN expression in MSC by 1.69- and 2.12-fold
respectively. On the other hand
ELP serum down-regulated MMP-9 and cathepsin K expression of RAW264.7 cell by 0.46- and 0.36-fold
respectively. The serum of the animals fed with ELP contains active ingredients which are effective in promoting osteogenesis and inhibiting osteoclastogenesis.
关键词
OsteoporosisseropharmacologyosteogenesisHerbal Formula
Keywords
OsteoporosisseropharmacologyosteogenesisHerbal Formula
references
Phillips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988;9:271–279.
Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992;13:7–15.
Sutton EE, Riche DM. Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis. Ann Pharmacother 2012;46:1000–1009.
Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Tan L, et al. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pac J Trop Med 2012;5:743–748.
Eriksen EF. Hormone replacement therapy or SERMS in the long term treatment of osteoporosis. Minerva Ginecol 2012;64:207–221.
Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol 2012;64:181–194.
Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038–1041.
Deal CL and Draper MW. Raloxifene: a selective estrogenreceptor modulator for postmenopausal osteoporosis—a clinical update on efficacy and safety. Womens Health (Lond Engl) 2006;2:199–210.
Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346–350.
Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095–1102.
Migliorati CA, Siegel MA, Elting LS. Bisphosphonateassociated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508–514.
Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, et al. Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine 2008;75:34–40.
Zhang JF, Li G, Chan CY, Meng CL, Lin MC, Chen YC, et al. Flavonoids of Herba Epimedii regulate osteogenesis of human mesenchymal stem cells through BMP and Wnt/beta-catenin signaling pathway. Mol Cell Endocrinol 2010;314:70–74.
Bian Q, Huang JH, Liang QQ, Shu B, Hou W, Xu H, et al. The osteogenetic effect of astragaloside IV with centrifugating pressure on the OCT-1 cells. Pharmazie 2011;66:63–68.
Liang W, Lin M, Li X, Li C, Gao B, Gan H, et al. Icariin promotes bone formation via the BMP-2/Smad4 signal transduction pathway in the hFOB 1.19 human osteoblastic cell line. Int J Mol Med 2012;30:889–895.
Sun Y, Lee SM, Wong YM, Lau CP, Shaw PC, Qin L, et al. Dosing effects of an antiosteoporosis herbal formula—a preclinical investigation using a rat model. Phytother Res 2008;22:267–273.
Siu WS, Wong HL, Lau CP, Shum WT, Wong CW, Gao S, et al. The effects of an antiosteoporosis herbal formula containing Epimedii Herba, Ligustri Lucidi Fructus and Psoraleae Fructus on density and structure of rat long bones under tail-suspension, and its mechanisms of action. Phytother Res 2013:27:484–492
Cheng Y, Liu Y, Wang H, Li J, Ren J, Zhu L, et al. A 26-week repeated dose toxicity study of Xian-ling-gu-bao in Sprague-Dawley rats. J Ethnopharmacol 2013;145:85–93.
Leung PC, Cheng KF, Chan YH. An innovative herbal product for the prevention of osteoporosis. Chin J Integr Med 2011;17:744–749.
Shih WT, Yang YH, Chen PC. Prescription patterns of Chinese herbal products for osteoporosis in Taiwan: a population-based study. Evid Based Complement Alternat Med 2012;2012:752837. doi: 10.1155/2012/752837.
Wang ZQ, Li JL, Sun YL, Yao M, Gao J, Yang Z, et al. Chinese herbal medicine for osteoporosis: a systematic review of randomized controlled trails. Evid Based Complement Alternat Med 2013;2013:356260.
Iwama H, Amagaya S, Ogihara YJ. Effect of shosaikoto, a Japanese and Chinese traditional herbal medicinal mixture, on the mitogenic activity of lipopolysaccharide: a new pharmacological testing method. J Ethnopharmacol 1987;21:45–53.
Xie F, Wu CF, Lai WP, Yang XJ, Cheung PY, Yao XS, et al. The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med 2005;2:353–361.
Zhang W, Ma D, Zhao Q, Ishida T. The effect of the major components of Fructus Cnidii on osteoblasts in vitro. J Acupunct Meridian Stud (Chin) 2010;3:32–37.
Ko CH, Siu WS, Lau CP, Lau CBS, Fung KP, Leung PC. Osteoprotective effects of Fructus Ligustri Lucidi aqueous extract in aged ovariectomized rats. Chin Med 2010;5:39.
Zhang Y, Leung PC, Che CT, Chow HK, Wu CF, Wong MS. Improvement of bone properties and enhancement of mineralization by ethanol extract of Fructus Ligustri Lucidi. Br J Nutr 2008;99:494–502.
Chen WF, Mok SK, Wang XL, Lai KH, Lai WP, Luk HK, et al. Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. Br J Nutr 2011;105:180–189.
Leung PC, Ko CHE, Siu WS, Pang SYE, Cheng KF, Chan YH. Developing an effective food supplement for the prevention of osteoporosis. J Funct Foods Health Dis 2011;9:379–388.
Cheung WI, Tse ML, Ngan T, Lin J, Lee WK, Poon WT, et al. Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. Clin Toxicol (Phila) 2009;47:683–685.
Ko CH, Siu WS, Wong HL, Gao S, Shum WT, Lau CP, et al. In vivo study on the pharmacological interactions between a Chinese herbal formula ELP and antiresorptive drugs to counteract osteoporosis. Evid Based Complement Alternat Med. 2012;2012:203732.
Mok SK, Chen WF, Lai WP, Leung PC, Wang XL, Yao XS, et al. Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptordependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 2010;159:939–949.
Zhao J, Ohba S, Komiyama Y, Shinkai M, Chung UI, Nagamune T. Icariin: a potential osteoinductive compound for bone tissue engineering. Tissue Eng Part A 2010;16:233–243.
Ming LG, Chen KM, Xian CJ. Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. J Cell Physiol 2013;228:513–521.
Chen KM, Ge BF, Liu XY, Ma PH, Lu MB, Bai MH, et al. Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie 2007;62:388–391.
Huang J, Yuan L, Wang X, Zhang TL, Wang K. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci 2007;81:832–840.
Hsieh TP, Sheu SY, Sun JS, Chen MH. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1a and PGE2 synthesis. Phytomedicine 2011;18:176–185.
Chen Q, Yang L, Zhang G, Wang F. Bioactivity-guided isolation of antiosteoporotic compounds from Ligustrum lucidum. Phytother Res 2012. doi: 10.1002/ptr.4820.
Zhang JK, Yang L, Meng GL, Yuan Z, Fan J, Li D, et al. Protection by salidroside against bone loss via inhibition of oxidative stress and bone-resorbing mediators. PLoS One 2013;8:e57251.
Tang DZ, Yang F, Yang Z, Huang J, Shi Q, Chen D, et al. Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochem Biophys Res Commun 2011;405:256–261.
Yang Z, Huang JH, Liu SF, Zhao YJ, Shen ZY, Wang YJ, et al. The osteoprotective effect of psoralen in ovariectomyinduced osteoporotic rats via stimulating the osteoblastic differentiation from bone mesenchymal stem cells. Menopause 2012;19:1156–1164.
Li G, Chan CY, Zhang JF, Zhang XA, Yew DT, He ML, et al. The aqueous extract of Fructus Ligustri Lucidi regulates the differentiation of mesenchymal stem cells. Internat J Integr Biol 2008;3:182–190.
Li G, Zhang XA, Zhang JF, Chan CY, Yew DT, He ML, et al. Ethanol extract of Fructus Ligustri Lucidi promotes osteogenesis of mesenchymal stem cells. Phytother Res 2010;24:571–576.
0
Views
0
Downloads
5
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
